Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences' TissueCypher Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients With Barrett's Esophagus
Castle Biosciences CEO Sells Over $158k in Company Stock
Express News | Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
Castle Biosciences' Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
Castle Biosciences (NASDAQ:CSTL) Is Using Debt Safely
DecisionDx-Melanoma Can Identify Melanoma Patients With Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms
Insider Sale: COO Kristen Oelschlager Sells Shares of Castle Biosciences Inc (CSTL)
Castle Biosciences Announced Publication Of A New Study In Future Oncology Further Substantiating Use Of Its DecisionDx-SCC Test In Guiding Patient Selection And Decision-making Related To The Use Of Art In Patients With High-risk Cutaneous Squamous...
Express News | Study Confirms the Ability of Castle Biosciences' Decisiondx®-Scc Test to Predict Likelihood of Benefit From Adjuvant Radiation Therapy in Patients With High-Risk Cutaneous Squamous Cell Carcinoma
Study Confirms the Ability of Castle Biosciences' DecisionDx-SCC Test to Predict Likelihood of Benefit From Adjuvant Radiation Therapy in Patients With High-Risk Cutaneous Squamous Cell Carcinoma
Castle Biosciences to Participate in Upcoming Investor Conferences
Analysts' Top Healthcare Picks: Encompass Health (EHC), Castle Biosciences (CSTL)
Castle Biosciences (CSTL) Receives a Buy From Scotiabank
Castle Biosciences Surpasses Financial Forecasts With Strong Q2 Revenue, Optimistic Growth, and Strategic Expansion
Castle Biosciences Price Target Maintained With a $37.00/Share by Stephens & Co.
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $34
Lake Street analyst Thomas Flaten maintains $Castle Biosciences(CSTL.US)$ with a buy rating, and maintains the target price at $34.According to TipRanks data, the analyst has a success rate of 40.1%
Express News | Castle Biosciences Inc : Btig Raises Target Price to $35 From $32
Castle Biosciences Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results and Increased Its FY24 Revenue Guidance Above Estimates.